A phase I study combining bendamustine with rituximab, etoposide and carboplatin (TREC) in patients with aggressive relapsed or refractory lymphoma

被引：0
|
作者：
Budde, L. Elizabeth
Martin, Daniel B.
Philip, Mary
Shustov, Andrei R.
Gooley, Theodore
Chen, Tara L.
Libby, Edward N.
Chen, Eric Y.
Kojouri, Kiarash
Langerak, Alan
Roden, Jennifer E.
Kammerer, Britt E.
Knudsen, Nancy L.
Smith, Stephen Douglas
Press, Oliver W.
Gopal, Ajay K.
机构：
[1] City Hope Natl Med Ctr, Duarte, CA 91010 USA
[2] Seattle Canc Care Alliance, Seattle, WA USA
[3] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA
[4] Univ Washington, Seattle Canc Care Alliance, Seattle, WA 98195 USA
[5] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[6] Univ Washington, Sch Pharm, Seattle, WA 98195 USA
[7] Grp Hlth Permanente, Bellevue, WA USA
[8] Skagit Valley Hosp, Reg Canc Care Ctr, Mt Vernon, WA USA
[9] St Alphonsus Reg Med Ctr, Boise, ID USA
[10] Univ Washington, Seattle, WA 98195 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8533
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Full Dose Bendamustine (Treanda®) Can Be Safely Combined with Rituximab, Etoposide and Carboplatin (TREC): Results of a Phase I Trial in Patients with Relapsed or Refractory Lymphoma
    Budde, Lihua Elizabeth
    Andrei, Shustov R.
    Ted, Gooley
    Chen, Tara L.
    Libby, Edward N., III
    Palanca-Wessels, Maria Corinna
    Philip, Mary
    Martin, Daniel B.
    Cassaday, Ryan D.
    Kojouri, Kiarash
    Press, Oliver W.
    Gopal, Ajay K.
    BLOOD, 2012, 120 (21)
  • [2] Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial
    Budde, Lihua E.
    Wu, David
    Martin, Daniel B.
    Philip, Mary
    Shustov, Andrei R.
    Smith, Stephen D.
    Gooley, Ted A.
    Chen, Tara L.
    Libby, Edward N.
    Chen, Eric Y.
    Kojouri, Kiarash
    Langerak, Alan
    Roden, Jennifer E.
    Press, Oliver W.
    Gopal, Ajay K.
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 183 (04) : 601 - 607
  • [3] Phase I/II study of bendamustine in combination with ofatumumab, carboplatin, etoposide (BOCE) for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma
    Pan, Jonathan
    Ghimire, Sushil
    Alpdogan, S. Onder
    Chapman, Andrew
    Carabasi, Matthew
    DiMeglio, Martina
    Gong, Jerald
    Martinez-Outschoorn, Ubaldo
    Rose, Lewis
    Ramirez, Michael
    Wagner, John L.
    Weiss, Mark
    Flomenberg, Neal
    Pro, Barbara
    Porcu, Pierluigi
    Filicko-OHara, Joanne
    Gaballa, Sameh
    LEUKEMIA & LYMPHOMA, 2021, 62 (03) : 590 - 597
  • [4] Phase I study of bendamustine, rituximab, ibrutinib, and venetoclax in relapsed, refractory mantle cell lymphoma
    Grieve, Clare
    Joseph, Ashlee
    Drullinsky, Pamela
    Zelenetz, Andrew D.
    Hamlin, Paul
    Kumar, Anita
    LEUKEMIA & LYMPHOMA, 2024, 65 (02) : 235 - 241
  • [5] A phase I study of bendamustine, lenalidomide and rituximab in relapsed and refractory lymphomas
    Cheson, Bruce D.
    Crawford, Jeanette
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 169 (04) : 528 - 533
  • [6] Bortezomib, Bendamustine, and Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma: The Phase II VERTICAL Study
    Fowler, Nathan
    Kahl, Brad S.
    Lee, Peter
    Matous, Jeffrey V.
    Cashen, Amanda F.
    Jacobs, Samuel A.
    Letzer, Jeffrey
    Amin, Bipinkumar
    Williams, Michael E.
    Smith, Sonali
    Saleh, Alfred
    Rosen, Peter
    Shi, Hongliang
    Parasuraman, Sudha
    Cheson, Bruce D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (25) : 3389 - 3395
  • [7] Cost-comparison analysis of bendamustine, rituximab, etoposide and carboplatin (TREC) vs. RICE/R-DHAP in relapsed lymphoma.
    Bodding-Long, Anneliese M.
    Budde, L. Elizabeth
    Roden, Jennifer E.
    Gopal, Ajay K.
    Chen, Tara L.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [8] Ibrutinib With Bendamustine and Rituximab for Treatment of Patients With Relapsed/Refractory Aggressive B-Cell Lymphoma
    Kedmi, Meirav
    Ribakovsy, Elena
    Benjamini, Ohad
    Schiby, Ginette
    Barshack, Iris
    Raskin, Stephen
    Eshet, Yael
    Mehr, Ramit
    Horowitz, Netanel
    Gurion, Ronit
    Goldschmidt, Neta
    Perry, Chava
    Levi, Itai
    Aviv, Ariel
    Herzog-Tzarfati, Katrin
    Nagler, Arnon
    Avigdor, Abraham
    HEMATOLOGICAL ONCOLOGY, 2024, 42 (06)
  • [9] A Phase I Study of Gemcitabine and Bendamustine in Relapsed/Refractory Hodgkin Lymphoma
    Cohen, Jonathon B.
    Wei, Lai
    Maddocks, Kami J.
    Heffner, Leonard T.
    Langston, Amelia
    Flowers, Christopher
    Devine, Steven M.
    Blum, Kristie A.
    BLOOD, 2015, 126 (23)
  • [10] Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma: A Phase I Trial
    Kambhampati, Swetha
    Fakhri, Bita
    Ai, Weiyun Z.
    Kaplan, Lawrence D.
    Tuscano, Joseph M.
    Wieduwilt, Matthew J.
    Sudhindra, Akshay
    Cavallone, Erika
    Reiner, Jesika
    Aoun, Charlie
    Castillo, Miguel
    Martinelli, Michelle
    Ta, Teresa
    Le, Diem
    Padilla, Michelle
    Crawford, Erika
    Andreadis, Charalambos B.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (03): : 139 - 146
12345